FIELD: pharmaceutics.
SUBSTANCE: group of inventions can be used to prevent or treat metabolic disorders, selected from a group comprising obesity, metabolic syndrome, disorders associated with insulin deficiency or insulin resistance, diabetes mellitus, glucose intolerance, abnormal lipid metabolism, hyperglycemia, dyslipidemia, as well as diseases associated with intestinal barrier function, including inflammatory bowel disease, Crohn's disease and ulcerative colitis, irritable bowel syndrome, disturbed intestinal contractility, hypercholesterolemia and atherogenic dyslipidemia. Disclosed is a composition containing Akkermansia muciniphila and green tea extract. Also disclosed is a method of producing said composition and use of said composition to stimulate weight loss in a subject in need thereof.
EFFECT: invention provides excellent results on weight reduction, as well as improved intestinal barrier function.
14 cl, 7 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| STRAIN OF AKKERMANSIA MUCINIPHILA AND APPLICATION THEREOF | 2019 |
|
RU2777068C1 |
| METHODS FOR MODULATING INTESTINAL MICROBIOTA | 2017 |
|
RU2738265C2 |
| COMPOSITIONS AND METHODS FOR PREVENTING AND/OR TREATING VITAMIN B12 DEFICIENCY | 2017 |
|
RU2730870C2 |
| AKKERMANSIA MUCINIPHILA STRAIN AND ITS APPLICATION | 2019 |
|
RU2792651C2 |
| USE OF 5-PENTADECYLRESORCINOL TO INCREASE PROPORTION OF AKKERMANSIA MUCINIPHILA IN HUMAN MICROBIOME | 2023 |
|
RU2807743C1 |
| USE OF MICROBIAL COMMUNITIES FOR THE TREATMENT OF HUMANS AND ANIMALS | 2017 |
|
RU2758387C2 |
| USE OF MICROBIAL COMMUNITIES FOR TREATING HUMANS AND ANIMALS | 2017 |
|
RU2823233C2 |
| USE OF COMPOSITIONS CONTAINING BIFIDOBACTERIUM ANIMALIS SSP. LACTIS LMG P-28149 | 2015 |
|
RU2673341C2 |
| NEW APPLICATIONS AND METHODS | 2017 |
|
RU2765804C2 |
| PREBIOTIC FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH DISTURBED COMPOSITION OR FUNCTIONALITY OF THE INTESTINAL MICROBIOME | 2018 |
|
RU2799081C2 |
